Yin Xing Ye

Ginkgo biloba L.

Also known as: Ginkgo leaf(English) 银杏叶(Chinese)

Eunhaengyeop銀杏葉 은행엽 Yin Hsing Yeh

Updated October 5, 2026 · Not yet clinically reviewed

Yin Xing Ye
Philipp Franz von Siebold and Joseph Gerhard Zuccarini, 1870 · public domain, via Wikimedia Commons

Safety at a glance

Caution

6 recorded drug interactions, 2 major or contraindicated

Note

Contraindications or side effects are listed

No rule in our tables for this herb: pregnancy, breastfeeding, incompatible pairs (十八反 / 十九畏), herb–drug, dose ceiling. This is not a safety clearance.
Not graded —

No toxicity grade is recorded. Most herbs in the catalogue carry none.

Traditional Chinese Medicine

Category
regulating blood
Temperature
Neutral
Taste
Sweet,Bitter
Channels
Heart,Lung

Functions

Invigorates Blood and Dispels Stasis; Unblocks the Channels and Alleviates Pain; Astringes the Lungs and calms wheezing; Transforms Turbidity and Lowers Lipids

Traditional uses

Yin Xing Ye (ginkgo leaf) is a neutral-cool herb used in Chinese medicine for conditions related to Heart and Lung function and Blood circulation. Its most notable applications are for cognitive support in the elderly and for cardiovascular health — improving Blood circulation to the brain and heart to address memory decline, dizziness, tinnitus, and chest pain from Blood stasis and Qi deficiency. The ginkgo tree is one of the oldest living trees on Earth and is considered a sacred longevity symbol.

Western herbalism

Properties: antioxidant, astringent, tonic

Pharmacological effects

  • Smooth muscle (bronchodilator/spasmolytic): Alcoholic extract relaxed trachea and blocked histamine/ACh spasm and histamine asthma in guinea pigs; flavone bronchodilation antagonized by propranolol; flavonoids spasmolytic on guinea pig intestine.
  • Cardiovascular / cerebral: Leaf extract dilates vessels and improves flow in small and medium arteries; protected against cerebral ischemia (gerbil carotid ligation) and cytotoxic or vasogenic cerebral edema; antiradical and membrane-protective effects in vitro.
  • Antiatherosclerotic: In high-fat-fed rabbits, oral extract (10 mg/kg/24h) reduced lipid disturbances and plaque area (54.7% vs 85.5% at 12 weeks) and raised HDL.
  • PAF antagonism / antiplatelet: Ginkgolides A–C block PAF receptor binding; ginkgolide B most active (IC50 about 10^-7 M), inhibiting PAF platelet aggregation, thrombosis, PAF- and antigen-induced bronchoconstriction, and correcting hyperdynamic circulation in cirrhotic rats.

Source: Zhu YP. Chinese Materia Medica: Chemistry, Pharmacology and Applications. Harwood Academic, 1998, p. 509.

Formulas using this herb

2 of 2 formulas

Botanical

Ginkgo biloba L. (Ginkgoaceae) is a long-lived, deciduous, dioecious tree reaching 20-35 m or more, with a straight trunk and an initially pyramidal crown that broadens with age. The grey, deeply furrowed bark covers wood with characteristic short spur shoots. The distinctive fan-shaped leaves 5-10 cm wide have parallel, dichotomously forking veins and are usually bilobed on long shoots; they turn brilliant yellow in autumn before falling. Male trees bear pollen catkins; female trees produce naked ovules that develop into yellow, plum-like seeds with a fleshy, malodorous outer coat. Now extinct in the wild but widely cultivated and possibly persisting in eastern China, Ginkgo is a living relict of an ancient lineage. The leaves (Yin Xing Ye) are used in TCM and standardised in modern Western phytotherapy for circulatory and cognitive support.

Family
Ginkgoaceae
Pharmaceutical name
Folium Ginkgo
Parts used
leaf
Plant type
tree

Constituents

Flavonol glycosides of quercetin, kaempferol and isorhamnetin

Flavonol O-glycosides · standardised leaf extracts such as EGb 761 are adjusted to 22-27% flavonol glycosides

The dominant polyphenol fraction of the leaf and the basis of its antioxidant and microcirculatory claims. Standardisation to this range is what makes leaf extract trial data transferable between products; crude leaf tea is not equivalent to a standardised extract.

Ginkgolides A, B, C and J

Diterpene trilactones · about 2.8-3.4% of EGb 761

Structurally unique cage diterpenes found only in this genus. Ginkgolide B is a potent antagonist of platelet-activating factor, which is the mechanistic basis for both the claimed circulatory benefit and the theoretical bleeding concern attached to leaf extracts.

Bilobalide

Sesquiterpene trilactone · about 2.6-3.2% of EGb 761

The single most abundant terpene trilactone of the leaf, with neuroprotective activity in models of ischaemia and a documented modulating effect on GABAergic transmission, which is one reason ginkgo leaf products are discussed in relation to seizure threshold.

Ginkgolic acids (alkylphenols)

Alkylphenolic acids · restricted to less than 5 parts per million in EGb 761 and in the standardised leaf extract monographs

Cytotoxic and strongly allergenic contact sensitisers concentrated in the leaf and fruit pulp. Their deliberate removal is the main safety step in manufacturing standardised leaf extract, and products that are not deacidified carry a real risk of allergic dermatitis and mucosal irritation.

Biflavones (amentoflavone, bilobetin, ginkgetin, isoginkgetin)

Biflavonoids

Leaf-specific dimeric flavones that inhibit several cytochrome P450 enzymes in vitro. They are substantially depleted in refined extracts, so crude leaf preparations carry a larger biflavone load and a correspondingly less predictable metabolic interaction profile than standardised extract.

Proanthocyanidins

Condensed tannins · roughly 7% of standardised leaf extract

An antioxidant fraction of the leaf that contributes to free radical scavenging but is not thought to carry the specific pharmacology of the terpene trilactones.

Drug interactions

Efavirenz

Major · Falling efavirenz plasma concentrations with loss of virological suppression · Evidence level: Probable

In a 47-year-old man stable for two years on efavirenz, emtricitabine and tenofovir, efavirenz concentrations fell from a therapeutic 1.26 mg/l to a non-therapeutic 0.48 mg/l during ginkgo leaf use, with virological failure. The authors proposed induction of CYP3A4 and P-glycoprotein by the extract, principally by the terpenoid fraction. A second published case reported the same pattern.

Clinical note: Do not combine ginkgo leaf with efavirenz. Extend the same caution to other antiretrovirals and to narrow-therapeutic-index CYP3A4 substrates such as transplant immunosuppressants, where a fall in exposure is not recoverable.

CYP2C19 substrates (omeprazole, and by extension clopidogrel activation)

Moderate · Reduced exposure to the parent drug, with the size of the effect depending on the patient's CYP2C19 genotype · Evidence level: Probable

Eighteen healthy Chinese volunteers pre-genotyped for CYP2C19 took a single 40 mg dose of omeprazole before and after 12 days of Ginkgo biloba 140 mg twice daily. Ginkgo induced omeprazole hydroxylation in a genotype-dependent manner and simultaneously reduced the renal clearance of 5-hydroxyomeprazole, so co-administration with CYP2C19 substrates may significantly reduce their effect. The direction is induction, not inhibition, which for clopidogrel would mean more rather than less active metabolite.

Clinical note: Expect reduced proton pump inhibitor effect. Where a CYP2C19-dependent drug is doing something important, either separate it from the ginkgo or monitor the clinical endpoint rather than assuming stability.

Antiplatelet drugs (aspirin, clopidogrel) and NSAIDs

Moderate · Possible additive antiplatelet effect; spontaneous bleeding has been reported, though controlled data are largely reassuring · Evidence level: Possible

Ginkgolide B is a platelet-activating factor antagonist, which supplies a plausible additive mechanism. A retrospective review of 2,647 prescriptions containing ginkgo leaf extract found interactions in 12.94%, most often with antiplatelets, anticoagulants and NSAIDs, with clopidogrel and aspirin each at 2.61%. Against this, controlled human studies have generally not shown a measurable haemostatic effect, and a secondary analysis of a randomised placebo-controlled trial in probable Alzheimer's dementia found no effect of EGb 761 on coagulation or bleeding time. The residual concern rests on case reports rather than on demonstrated pharmacodynamic change.

Clinical note: There is no need to panic about aspirin plus a standardised leaf extract, but stop ginkgo one to two weeks before elective surgery or neuraxial procedures, and take any new bruising, epistaxis or unexplained headache seriously.

Warfarin

Minor · Controlled studies show no change in INR, warfarin pharmacokinetics or platelet aggregation; isolated bleeding case reports remain unexplained · Evidence level: Established

In an open-label three-way crossover study, 12 healthy men received a single 25 mg dose of warfarin alone or after seven days of ginkgo or ginger at recommended doses, with dosing continued for seven days afterwards. Platelet aggregation, INR, warfarin enantiomer protein binding and plasma concentrations, and urinary S-7-hydroxywarfarin were all measured, and neither ginkgo nor ginger altered INR or platelet aggregation. A separate crossover study in 21 warfarin-stabilised patients taking ginkgo 100 mg daily for four weeks likewise found no change in INR or warfarin dose requirement.

Clinical note: This is one of the herb-drug interactions that the evidence has largely retired. Continued INR monitoring is sensible on starting or stopping any herb, but a warfarin patient does not need to be told ginkgo leaf is forbidden.

Antiepileptic drugs (valproate, phenytoin)

Major · Breakthrough seizures, in one report fatal · Evidence level: Possible

A fatal breakthrough seizure was reported in an epileptic patient whose valproate and phenytoin concentrations were subtherapeutic while taking a ginkgo product, and a separate case described ginkgo precipitating epileptic seizures in an older patient. Two mechanisms are debated: induction of the metabolism of the anticonvulsants, and the pyridoxine antimetabolite 4'-O-methylpyridoxine, called ginkgotoxin. It is important to be exact about the second. Ginkgotoxin is a hazard of the ginkgo SEED, where it and its 5'-glucoside accumulate; total ginkgotoxin in 131 Chinese seed samples ranged from about 141 to 537 micrograms per gram. Leaf material carries far less, and leaf extract is not a recognised cause of the classical ginkgo-seed convulsant poisoning. The seizure reports involving leaf products are therefore a signal to respect, not an instance of seed toxicity.

Clinical note: Avoid ginkgo leaf in poorly controlled epilepsy. If a patient with epilepsy is already taking it, check anticonvulsant levels rather than assuming they are unchanged, and never substitute the seed (Bai Guo) where the leaf is intended.

Crude leaf preparations that have not been deacidified

Moderate · Allergic contact dermatitis, mucosal irritation and cytotoxicity from ginkgolic acids · Evidence level: Established

Ginkgolic acids are allergenic alkylphenols present in the leaf and heavily concentrated in the fruit pulp. Standardised extract monographs cap them below 5 parts per million precisely because of this, so a homemade leaf tea, a non-standardised powder or any preparation involving the fleshy seed coat delivers an exposure that the clinical trial literature was designed to exclude.

Clinical note: Prescribe a deacidified standardised leaf extract where the intent is to reproduce trial results. Handle fresh leaves and especially the fruit pulp with gloves; cross-sensitivity with urushiol-type allergens is described for the fruit.

Dosage

FormAmountFrequencyNotes
decoction9–12 gDaily
中国药典 2020 【用法与用量】9~12g。 【注意】有实邪者忌用。 【性味与归经】甘、苦、涩,平。归心、肺经。 — Chinese Pharmacopoeia 2020, quoted verbatim; route and cautions preserved. Replaces a cleared category-filler value.

Evidence

Study design on record, not certainty of outcome.

Systematic review / meta-analysis
2
Randomized controlled trial
3
Observational / case report
1

Ginkgo biloba for cognitive impairment and dementia

Birks J, Grimley Evans J · Cochrane Database of Systematic Reviews · 2009 · systematic review

Systematic review / meta-analysis · Not yet verified

The Cochrane review of randomised trials of ginkgo leaf extract in cognitive impairment and dementia concluded that the evidence of benefit is inconsistent and unreliable, while ginkgo appears safe in use with no excess of adverse events compared with placebo. It is the standard counterweight to the more favourable manufacturer-linked meta-analyses.

doi:10.1002/14651858.CD003120.pub3

Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia – a meta-analysis of patient subgroups in randomised controlled trials

Riepe M, Hoerr R, Schlaefke S · The World Journal of Biological Psychiatry · 2025 · systematic review

Systematic review / meta-analysis · Verified

Pooling patients with mild dementia, defined by a Short Cognitive Performance Test total score of 9 to 15, from four eligible randomised placebo-controlled trials and totalling 782 patients, EGb 761 at 240 mg daily was superior to placebo for cognition (p = 0.04), global assessment (p = 0.01), activities of daily living (p = 0.01) and quality of life (p = 0.02). The result applies to treatment of established mild dementia, not to prevention, and the author group includes the extract manufacturer.

doi:10.1080/15622975.2024.2446830

Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD · JAMA · 2008 · RCT

Randomized controlled trial · Not yet verified

The Ginkgo Evaluation of Memory study randomised 3,069 community volunteers aged 75 or older, 2,587 with normal cognition and 482 with mild cognitive impairment, to EGb 761 120 mg twice daily or placebo across five United States academic centres, with a median follow-up of 6.1 years. Ginkgo leaf extract did not reduce the incidence of all-cause dementia or Alzheimer's disease, and did not slow progression in those who began with mild cognitive impairment.

doi:10.1001/jama.2008.683

Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S · The Lancet Neurology · 2012 · RCT

Randomized controlled trial · Verified

A long-term randomised placebo-controlled prevention trial of standardised ginkgo leaf extract in older adults reporting memory complaints. Long-term use did not reduce the risk of progression to Alzheimer's disease, reinforcing the negative prevention result seen in the Ginkgo Evaluation of Memory study.

doi:10.1016/S1474-4422(12)70206-5

Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ · British Journal of Clinical Pharmacology · 2005 · RCT

Randomized controlled trial · Verified

Open-label three-way crossover in 12 healthy men given a single 25 mg dose of warfarin alone or after seven days of ginkgo or ginger, with herb dosing continued for a further seven days. Neither herb altered INR, platelet aggregation, warfarin enantiomer protein binding or plasma concentrations, or urinary S-7-hydroxywarfarin. The study is the main reason the ginkgo-warfarin interaction is now regarded as far weaker than early case reports suggested.

doi:10.1111/j.1365-2125.2005.02322.x

Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis

Mai NTQ, Hieu NV, Ngan TT, Van Anh T, Van Linh P, Thu Phuong NT · PLOS ONE · 2025 · cohort

Observational / case report · Verified

Retrospective review of 2,647 prescriptions containing ginkgo leaf extract at a Vietnamese hospital between January 2022 and December 2023 identified potential interactions in 342, a prevalence of 12.94%. The most frequent partners were antiplatelets, anticoagulants and NSAIDs, with clopidogrel and aspirin each at 2.61%; interactions with direct oral anticoagulants and acenocoumarol were not statistically significant in the analysis.

doi:10.1371/journal.pone.0321804

Safety

Contraindications

Its use is cautious in pregnant women, and prohibited in patients with excess pathogen.

Source: Xi S, Gong Y. Essentials of Chinese Materia Medica and Medical Formulas. Academic Press/Elsevier, 2017, pp. 230–235.

Cultural and historical

Dian Nan Ben Cao · Ming dynasty, 1436

Lan Mao's regional Yunnan materia medica is the earliest mention of the ginkgo leaf as a drug in its own right, used externally for sores of the skin and scalp and for freckles. The leaf's classical record is thin and external; the internal cardiovascular and cognitive indications are twentieth-century.

Ben Cao Pin Hui Jing Yao · Ming dynasty, 1505

Liu Wentai's imperial compilation is the first official materia medica to admit the ginkgo leaf, several centuries after the seed had entered court use. The compilation was suppressed after Liu was blamed for the death of the Hongzhi emperor and was not recovered until 1926.

Ben Cao Gang Mu · Ming dynasty, 1596

The principal ginkgo entry here is Bai Guo, the seed, which is a different drug with a different hazard profile from the leaf and is recorded for cough, wheeze and urinary frequency. Practitioners reading classical sources on ginkgo should check whether the seed or the leaf is meant before transferring any indication.

References

  1. Wiegman DJ, Brinkman K, Franssen EJF. Interaction of Ginkgo biloba with efavirenz. AIDS. 2009 doi:10.1097/QAD.0b013e32832c412b
  2. Naccarato M, Yoong D, Gough K. A Potential Drug–Herbal Interaction between Ginkgo biloba and Efavirenz. Journal of the International Association of Physicians in AIDS Care. 2012 doi:10.1177/1545109711435364
  3. Kupiec T, Raj V. Fatal Seizures Due to Potential Herb-Drug Interactions with Ginkgo Biloba. Journal of Analytical Toxicology. 2005 doi:10.1093/jat/29.7.755
  4. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age and Ageing. 2001 doi:10.1093/ageing/30.6.523
  5. Liu Y, Xin H, Zhang Y, Che F, Shen N, Cui Y. Leaves, seeds and exocarp of Ginkgo biloba L. (Ginkgoaceae): A Comprehensive Review of Traditional Uses, phytochemistry, pharmacology, resource utilization and toxicity. Journal of Ethnopharmacology. 2022 doi:10.1016/j.jep.2022.115645
  6. Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.. Pharmacogenetics. 2004 doi:10.1097/00008571-200412000-00007
© Verscienta Health — use subject to the API terms at https://verscienta.com/developers/api; educational reference, not medical advice